Sentinel lymph node biopsy and axillary dissection in breast cancer: Results in a large series

Journal of the National Cancer Institute

Volumn 91, Issue 4, 1999, Pages 368-373

  Veronesi, Umberto ^a   Paganelli, Giovanni ^a   Viale, Giuseppe ^a   Galimberti, Viviana ^a   Luini, Alberto ^a   Zurrida, Stefano ^a   Robertson, Chris ^a   Sacchini, Virgilio ^a   Veronesi, Paolo ^a   Orvieto, Enrico ^a   De Cicco, Concetta ^a   Intra, Mattia ^a   Tosi, Giampiero ^a   Scarpa, Daniela ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

SERUM ALBUMIN TC 99M; TRACER;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER STAGING; HUMAN; LYMPH NODE BIOPSY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHOSCINTIGRAPHY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SCINTILLATION CAMERA;

EID: 0033577056     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/91.4.368     Document Type: Article

References (37)

1. Tabar L, Fagerberg G, Duffy SW, Day NE, Gad A, Grontoft O. Update of the Swedish two-county program of mammographic screening for breast cancer. Radiol Clin North Am 1992;30:187-210.
2. Veronesi U, Salvadori B, Luini A, Greco M, Saccozzi R, del Vecchio M, et al. Breast conservation is a safe method in patients with small cancer of the breast. Long-term results of three randomised trials on 1,973 patients. Eur J Cancer 1995;31A:1574-9.
3. Baxter N, McCready D, Chapman JA, Fish E, Kahn H, Hanna W, et al. Clinical behavior of untreated axillary nodes after local treatment for primary breast cancer. Ann Surg Oncol 1996;3:235-40.
4. Fisher B, Redmond C, Fisher ER, Bauer M, Wolmark N, Wickerham DL, et al. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation, N Engl J Med 1985;312: 674-81.
5. Harris JR, Lippman ME, Veronesi U, Willett W. Breast cancer (2). N Engl J Med 1992;327: 390-8.
6. Dershaw DD, Panicek DM, Osborne MP. Significance of lymph nodes visualized by the mammographic axillary view. Breast Dis 1991; 4:271-80.
7. Veronesi U, Luini A, Galimberti V, Marchini S, Sacchini V, Rilke F. Extent of metastatic axillary involvement in 1446 cases of breast cancer. Eur J Surg Oncol 1990;16:127-33.
8. Veronesi U, Galimberti V, Zurrida S, Merson M, Greco M, Luini A. Prognostic significance of number and level of axillary node metastases in breast cancer. The Breast 1993;2:224-8.
9. Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127: 392-9.
10. van der Veen H, Hoekstra OS, Paul MA, Cuesta MA, Meijer S. Gamma probe-guided sentinel node biopsy to select patients with melanoma for lymphadenectomy. Br J Surg 1994;81:1769-70.
11. Joseph E, Brobeil A, Glass F, Glass J, Messina J, DeConti R, et al. Results of complete lymph node dissection in 83 melanoma patients with positive sentinel nodes. Ann Surg Oncol 1998; 5:119-25.
12. Giuliano AE. Sentinel lymphadenectomy in primary breast carcinoma: an alternative to routine axillary dissection [editorial]. J Surg Oncol 1996;62:75-7.
13. Albertini JJ, Lyman GH, Cox C, Yeatman T, Balducci L, Ku N, et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA 1996;276:1818-22.
14. Veronesi U, Paganelli G, Galimberti V, Viale G, Zurrida S, Bedoni M, et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet 1997;349:1864-7.
15. De Cicco C, Paganelli G, Cremonesi M, Galimberti V, Bartolomei M, Viale G, et al. Gamma-probe guided resection of the sentinel node in breast cancer. Eur J Nucl Med 1997; 24:892.
16. Gulec SA, Moffat FL, Carroll RG. The expanding clinical role for intraoperative gamma probes. In: Freeman LM, editor. Nuclear medicine annual. Philadelphia (PA): Lippincott-Raven; 1997. p. 209-37.
17. Berg JW. The significance of axillary node level of breast cancer. Cancer 1955;8:776-8.
18. World Health Organization. Histological typing of breast tumors. 2nd ed. International histological classification of tumors No. 2. Geneva (Switzerland): WHO; 1981.
19. Rosen PP, Oberman HA. Tumors of the mammary gland. Washington (DC): Armed Forces Institute of Pathology; 1993.
20. Ellson CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19:403-10.
21. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981;29: 577-80.
22. Doglioni C, Tos AP, Laurino L, Iuzzolino P, Chiarelli C, Celio MR, et al. Calretinin: a novel immunocytochemical marker for mesothelioma. Am J Surg Pathol 1996;20: 1037-46.
23. Directive 96/29 EURATOM, May 13, 1996.
24. Publication 60. 1990 Recommendations of the International Commission on Radiological Protection. Annals of the ICRP - Vol 21 (1-3). Oxford (U.K.): Pergamon Press; 1991.
25. Zar JH. Biostatistical analysis. 2nd ed. Englewood Cliffs (NJ): Prentice-Hall; 1984.
26. Edgington EW. Randomisation tests. 2nd ed. New York (NY): Marcel Dekker; 1987.
27. Reintgen D. What is the role and impact of the sentinel node sampling technique in breast cancer staging? Cancer Control: JMCC 1997;4: 5-8.
28. Krag DN, Weaver D, Ashikaga T, Moffat F, Klimberg VS, Sheiver C, et al. The sentinel node in breast cancer. A multicenter validation study. N Engl J Med 1998;330:941-6.
29. Lin PP, Allison DC, Wainstock J, Miller KD, Dooley WC, Friedman N, et al. Impact of axillary lymph node dissection on the therapy of breast cancer patients. J Clin Oncol 1993;11: 1536-44.
30. Reynolds JV, Mercer P, McDermott EWM, Cross S, Stokes M, Murphy D, et al. Audit of complete axillary dissection in early breast cancer. Eur J Cancer 1994;30A:148-9.
31. Tabar L, Fagerberg G, Chen HH, Duffy SW, Smart CR, Gad A, et al. Efficacy of breast cancer screening by age. New results from the Swedish Two-County Trial. Cancer 1995;75: 2507-17.
32. Goldhirsch A, Gelber RD, Castiglione M, Price KN, Rudenstam CM, Lindtner J, et al. Present and future projects of the International Breast Cancer Study Group. Cancer 1994;74(3 Suppl): 1139-49.
33. Silvestrini R, Veneroni S, Benini E, Daidone MG, Luisi A, Leutner M, et al. Expression of p53, glutalhione S-transferase-π, and Bcl-2 proteins and benefit from adjuvant radiotherapy in breast cancer. J Natl Cancer Inst 1997;89:639-45.
34. Ravdin PM, De Laurentus M, Vendely T, Clark GM. Prediction of axillary lymph node status in breast cancer patients by use of prognostic indicators. J Natl Cancer Inst 1994;86:1171-5.
35. Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997;15:2483-93.
36. International (Ludwig) Breast Cancer Study Group. Prognostic importance of occult axillary micrometastases from breast cancer. Lancet 1990;335:1565-8.
37. Turner RR, Ollila DW, Krasne DL, Giuliano AE. Histopathologic validation of the sentinel lymph node hypothesis for breast carcinoma. Ann Surg 1997;226:271-8.